Biosimilars may now be substituted for brand-name biologics in Massachusetts as long as the pharmacist informs both the prescribing physician and consumer of the change. The Biotechnology Industry Organization, which has been promoting such legislation, said in a statement, that the law, passed in June, “maintains incentives for innovation and promotes a competitive market for biologic therapies.” The first such bill was signed into law in February of last year in Virginia.
About this article
Cite this article
Biosimilar substitution in Massachusetts. Nat Biotechnol 32, 709 (2014). https://doi.org/10.1038/nbt0814-709d